Uncategorized
Clinical trial to evaluate safety, efficacy of sustained-release drug delivery implant for glaucoma
MILAN — A phase 2a clinical trial will evaluate the safety, tolerability and efficacy of an intracameral implant for sustained delivery of a prostaglandin formulation in patients with ocular hypertension or early glaucoma. ENV515 (Envisia Therapeutics) is made of a biodegradable polymer containing travoprost and has successfully undergone preclinical studies, showing sustained IOP lowering efficacy for up to 8 months after a single dose, Jay S. Pepose, MD, PhD, said at the annual joint meeting of Ocular Surgery News and the Italian Ophthalmological Society.